Ventricular Tachycardia：A Registry Study

July 27, 2026 updated by: Beijing Anzhen Hospital
Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Beijing, China
        • Recruiting
        • Beijing Anzhen Hospital, Capital Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention, in the presence of structural heart disease. Participants will be consecutively enrolled from multiple hospitals in China and managed according to routine clinical practice.

Description

Inclusion Criteria:

  • Adults aged ≥18 years.
  • Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study.
  • Structural heart disease diagnosed according to current clinical guidelines.
  • Willing and able to provide written informed consent.
  • Willing to comply with the study follow-up schedule.

Exclusion Criteria:

  • Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances).
  • Idiopathic ventricular tachycardia without evidence of structural heart disease.
  • Cardiac surgery within 60 days before enrollment.
  • Severe infectious diseases (e.g., septic shock or sepsis).
  • Severe coagulation disorders, including platelet count <50 × 10⁹/L or disseminated intravascular coagulation.
  • Participation in another interventional clinical study that may interfere with this registry.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SHD-VT Cohort
This cohort includes consecutive adult patients with structural heart disease and documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, enrolled in a prospective multicenter observational registry. All treatment decisions are made according to routine clinical practice without study intervention.
Other: Standard Clinical Care
Participants will receive standard clinical care as determined by their treating physicians. Treatment strategies, including antiarrhythmic drug therapy, catheter ablation, implantable cardioverter-defibrillator (ICD) implantation, cardiac resynchronization therapy with defibrillator (CRT-D), surgical interventions, and other clinically indicated therapies, will be recorded. No treatment is assigned or influenced by the study protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite of ventricular tachycardia recurrence or appropriate ICD therapy, unplanned cardiovascular hospitalization, or all-cause death
Time Frame: 12 months
Time to the first occurrence of ventricular tachycardia recurrence or appropriate implantable cardioverter-defibrillator (ICD) therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ventricular tachycardia recurrence or appropriate ICD therapy
Time Frame: 12 months
Time to the first documented ventricular tachycardia recurrence or first appropriate implantable cardioverter-defibrillator (ICD) therapy, when applicable.
12 months
Unplanned cardiovascular hospitalization
Time Frame: 12 months
Time to the first unplanned hospitalization for cardiovascular causes.
12 months
Causes and number of unplanned cardiovascular hospitalizations
Time Frame: 12 months
Causes of unplanned cardiovascular hospitalizations and the total number of hospitalization episodes during follow-up.
12 months
Causes and number of cardiovascular emergency department visits
Time Frame: 12 months
Causes and total number of emergency department visits for cardiovascular conditions during follow-up.
12 months
All-cause mortality
Time Frame: 12 months
Death from any cause during follow-up.
12 months
Cardiovascular mortality
Time Frame: 12 months
Death attributable to cardiovascular causes during follow-up.
12 months
Change in health-related quality of life (SF-36)
Time Frame: Baseline to 12 months
Change in the Short Form-36 (SF-36) score from baseline.
Baseline to 12 months
Change in patient-reported outcome measures
Time Frame: Baseline to 12 months
Change from baseline in patient-reported outcomes, including the Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Pittsburgh Sleep Quality Index (PSQI), and other validated scales, as applicable.
Baseline to 12 months
Treatment-related major safety events
Time Frame: 12 months
Occurrence of treatment-related major safety events, including catheter ablation-related complications, ICD-related complications, serious adverse drug reactions, and other serious adverse events.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Anzhen Hospital

Investigators

  • Principal Investigator: Deyong Long, Beijing Anzhen Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2025

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

August 24, 2025

First Submitted That Met QC Criteria

August 24, 2025

First Posted (Actual)

September 2, 2025

Study Record Updates

Last Update Posted (Actual)

July 29, 2026

Last Update Submitted That Met QC Criteria

July 27, 2026

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KS2025135

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe